01 Jun 2019 ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
31 May 2019 Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
31 May 2019 U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
31 May 2019 Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial
31 May 2019 GT Biopharma GTB-1550 Clinical Development Update
30 May 2019 Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)
30 May 2019 Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH
29 May 2019 ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer’s Disease with Selectivity for the Neurotoxic Form of Tau
28 May 2019 European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review
24 May 2019 Immunovant Initiates Dosing in ASCEND-GO 1, a Phase 2a Trial of IMVT-1401 in Patients with Graves' Ophthalmopathy (GO)
23 May 2019 Alteogen Inc. gets IND approval for a clinical study in Korea for Eylea Biosimilar (ALT-L9)
22 May 2019 Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
22 May 2019 Entyvio® (vedolizumab) Approved in Japan for the Treatment of Patients with Moderately to Severely Active Crohn's Disease
22 May 2019 argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
21 May 2019 Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
21 May 2019 Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation
21 May 2019 Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer
18 May 2019 Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
18 May 2019 AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
15 May 2019 NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute
15 May 2019 ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer
15 May 2019 FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma
14 May 2019 AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
14 May 2019 FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy
13 May 2019 Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up